Literature DB >> 7770514

The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA).

K Rittenhouse-Diakun1, H Van Leengoed, J Morgan, E Hryhorenko, G Paszkiewicz, J E Whitaker, A R Oseroff.   

Abstract

Endogenously generated protoporphyrin IX (PpIX) from exogenous ALA can be an effective photosensitizer. PpIX accumulation is inversely dependent on available intracellular iron, which is required for the conversion of PpIX to heme. Iron also is necessary for cell replication. Since iron can be toxic, intracellular iron levels are tightly controlled. Activated and proliferating cells respond to the demand for intracellular iron by upregulating membrane expression of the transferrin receptor (CD71) which is needed for iron uptake. We predicted that activated lymphocytes (CD71+) would preferentially accumulate PpIX because of their lower intracellular iron levels and because of competition for iron between ALA-induced heme production and cellular growth processes. Thus, the CD71+ cells could serve as PDT targets. Stimulation of human peripheral blood lymphocytes (PBL) with the mitogens, phytohemagglutinin A, concanavalin A and pokeweed prior to incubation with ALA results in PpIX accumulation correlating with level of activation. Activated lymphocytes expressing high levels of surface CD71 transferrin receptors generated more PpIX than those with low CD71 expression. Incubating activated cells in transferrin depleted medium (thereby decreasing the iron availability) further increased PpIX levels. Malignant, CD71+ T lymphocytes from a patient with cutaneous T-cell lymphoma (CTCL)/Sezary syndrome also accumulated increased PpIX levels in comparison to normal lymphocytes. PDT of activated lymphocytes and Sezary cells after ALA incubation demonstrated preferential killing compared to normal, unstimulated PBL. These findings suggest a possible mechanism for the selectivity of ALA PDT for activated CD71+ cells. They also indicate a clinical use for ALA-PDT in therapy directed towards the malignant lymphocytes in leukemias and lymphomas, and as animmunomodulatory agent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7770514     DOI: 10.1111/j.1751-1097.1995.tb02356.x

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  18 in total

1.  Activated T cells exhibit increased uptake of silicon phthalocyanine Pc 4 and increased susceptibility to Pc 4-photodynamic therapy-mediated cell death.

Authors:  David C Soler; Jennifer Ohtola; Hideaki Sugiyama; Myriam E Rodriguez; Ling Han; Nancy L Oleinick; Minh Lam; Elma D Baron; Kevin D Cooper; Thomas S McCormick
Journal:  Photochem Photobiol Sci       Date:  2016-05-10       Impact factor: 3.982

Review 2.  Therapeutic advances in cutaneous T-cell lymphoma.

Authors:  Oleg E Akilov; Larisa Geskin
Journal:  Skin Therapy Lett       Date:  2011-02

Review 3.  The immunosuppressive side of PDT.

Authors:  Pawel Mroz; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2011-03-24       Impact factor: 3.982

Review 4.  Innovative therapy of cutaneous T-cell lymphoma: beyond psoralen and ultraviolet light and nitrogen mustard.

Authors:  Brian Poligone; Peter Heald
Journal:  Dermatol Clin       Date:  2010-07       Impact factor: 3.478

5.  A case of late-onset multiple sclerosis mimicking glioblastoma and displaying intraoperative 5-aminolevulinic acid fluorescence.

Authors:  U Nestler; A Warter; P Cabre; N Manzo
Journal:  Acta Neurochir (Wien)       Date:  2012-03-09       Impact factor: 2.216

6.  Factors affecting aminolaevulinic acid-induced generation of protoporphyrin IX.

Authors:  L Wyld; J L Burn; M W Reed; N J Brown
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Effects of light fractionation and different fluence rates on photodynamic therapy with 5-aminolaevulinic acid in vivo.

Authors:  P Babilas; V Schacht; G Liebsch; O S Wolfbeis; M Landthaler; R-M Szeimies; C Abels
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

8.  Emerging treatment options for early mycosis fungoides.

Authors:  Montserrat Fernandez-Guarino
Journal:  Clin Cosmet Investig Dermatol       Date:  2013-02-18

9.  Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes.

Authors:  B Ortel; N Chen; J Brissette; G P Dotto; E Maytin; T Hasan
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

10.  The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells.

Authors:  K Berg; H Anholt; O Bech; J Moan
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.